Mattiuzzo Giada, Knezevic Ivana, Hassall Mark, Ashall James, Myhill Sophie, Faulkner Valwynne, Hockley Jason, Rigsby Peter, Wilkinson Dianna E, Page Mark
1Division of Virology, National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG UK.
2Department of Essential Medicines and Health Products, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland.
NPJ Vaccines. 2019 Oct 14;4:42. doi: 10.1038/s41541-019-0135-3. eCollection 2019.
During outbreaks of emerging viruses, such as the Zika outbreak in 2015-2016, speed and accuracy in detection of infection are critical factors to control the spread of the disease; often serological and diagnostic methods for emerging viruses are not well developed and validated. Thus, vaccines and treatments are difficult to evaluate due to the lack of comparable methods. In this study, we show how the 1st WHO International Standard for anti-Zika antibody was able to harmonize the neutralization titres of a panel of serological Zika-positive samples from laboratories worldwide. Expression of the titres in International Unit per millilitre reduced the inter-laboratory variance, allowing for greater comparability between laboratories. We advocate the use of the International Standard for anti-Zika virus antibodies for the calibration of neutralization assays to create a common language, which will permit a clear evaluation of the results of different clinical trials and expedite the vaccine/treatment development.
在新兴病毒爆发期间,如2015 - 2016年的寨卡病毒爆发,感染检测的速度和准确性是控制疾病传播的关键因素;新兴病毒的血清学和诊断方法往往尚未得到充分发展和验证。因此,由于缺乏可比的方法,疫苗和治疗方法难以评估。在本研究中,我们展示了世界卫生组织首个抗寨卡病毒抗体国际标准如何能够使来自全球实验室的一组寨卡病毒血清学阳性样本的中和效价趋于一致。以每毫升国际单位表示效价降低了实验室间的差异,使各实验室之间具有更高的可比性。我们提倡使用抗寨卡病毒抗体国际标准来校准中和试验,以创造一种通用语言,这将有助于清晰评估不同临床试验的结果,并加快疫苗/治疗方法的研发。